As Philipp Toleikis, CEO of Sernova, himself indicates, there will probably be a licensing deal. Numerous conditions and details have to be worked out to ensure legal certainty for both parties. In my opinion, we now seem to be in this decisive phase of negotiations, in which the lawyers and notaries of the contracting parties are busy with the signing of the contract.
According to the CEO PHILIP TOLEIKIS:
1.the bag is safe
The bag will heal people,
which should be considered as a medical revolution.
---- and more. I think that behind the scenes already with a
"Medtech company" the distribution network is being built.
There is speculation about which big pharma company might be in line for a deal. For years Sernova has cherished the cooperation with: Medtronic.
Source: Sernova Corp February 22, 2018, 6:00 a.m. EDT
LONDON, ONTARIO - (Globe Newswire - February 22, 2018) - Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing regenerative medicine technologies for the treatment of chronic diseases including diabetes and hemophilia, is pleased to announce continuous glucose monitoring systems (CGM (Medtronic Minimed, Northridge, CA)) will be provided to patients in Sernova's US regenerative medicine clinical trial of its Cell Pouch(TM). CGM will be used to track the function of the transplanted cells in the measurement of key efficacy measures at multiple time points following transplantation of the therapeutic cells into the Cell Pouch.
As Redbaron correctly pointed out
the only thing that can be blamed on Philip Toleikis is the assessment of the time point of the licensing deal.
If one wants to defend him, one has to consider the above mentioned points, that a license deal is more difficult than a takeover and many, many details have to be considered and clarified. After all, there is a lot of money at stake.
I remain very optimistic and believe that we will receive the long-awaited news very soon.
*my very personal opinion!!